Novartis in Society Integrated Report

Report overview

The report describes Novartis's 2023 transformation into a focused innovative medicines company following the Sandoz spin-off. It reports USD 45.4 billion in full-year net sales and continued investment in research and development, including medicines for neglected tropical diseases and malaria. The company also reports global access strategies for all new medicines launched and further progress in reducing operational emissions, water consumption and waste.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status
CDP score

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Renewable energy
Water consumption
Waste
Employees
Women on the board
Women in management
Workplace fatalities
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services